← boardnext 2029-02
PDSB
PDS Biotechnology Corp.distress 7/10 · high distress / dilution risk$0.710%today-50% from 52w high
Oncology 1
Lead: Recurrent Head and Neck Cancer · target PD-1
Revenue
pre-revenue
Liquidity
$22M
Runway
0.9 yrs
Shares 1y
+20%
Price & events
-26.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
+0.3%
1W
-21.8%
1M
-23.1%
3M
-24.9%
6M
-42.9%
1Y
-83.1%
2Y
-92.8%
5Y
-68.7%
All
Overview
- Market Cap
- $39.82M
- Volume
- 16.73K
- 52 Week Range
- $0.54 – $1.43
- Total Shares
- 55.82M
- Float Shares
- 54.40M
- Short %
- 2.49%
- % Held by Insiders
- 1.51%
- % Held by Institutions
- 9.17%
- RVOL
- 0.04x
- Beta
- 1.58
Pipeline stages · 2 programs
Pembrolizumab Monotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pembrolizumab (KEYTRUDA®) and PDS0101PD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-02 Estimated 50% readout ~2029-04-17 | Phase 3 | Pembrolizumab Monotherapy | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma | — | active not recruiting |
| 2025-05-14 | Phase 2 | Pembrolizumab (KEYTRUDA®) and PDS0101 | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck | 95 | completed |
Catalyst news & presentations · 11
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-02-20fda agreementPDS0101 · FDA accepted protocol amendment for Phase 3 VERSATILE-003 including PFS as interim primary endpoint.SEC 8-K
- fourth quarter of 2025enrollment completesecondaryPhase 2PDS01ADC · Patient recruitment completion for Stage 2 of Phase 2 trialSEC 8-K
- 2025-12-02fda agreementPDS0101 · FDA accepted Type C meeting request to discuss proposed accelerated approval pathway.SEC 8-K
- November 10, 2025conferencedata presentationsecondaryPDS0101 · Rapid oral abstract presented at SITC 2025 showing immune biomarkers predict clinical activity.SEC 8-K
- November 10, 2025conferencedata presentationsecondaryPDS01ADC · Two poster presentations at SITC 2025 showing reprogramming of NK cells and stem-like T cells.SEC 8-K
- 2025-10-29enrollment delayPDS0101 · VERSATILE-003 trial temporarily paused pending FDA review of protocol amendmentSEC 8-K
- Q1 2025trial initiationsecondaryPhase 3Versamune HPV · Planned initiation of Phase 3 trial for Versamune HPV in HPV16-positive HNSCCSEC 8-K
- 2024trial initiationsecondaryPhase 3Versamune HPV · Plans to initiate a pivotal clinical trial in 2024.SEC 8-K
- mid-December 2024filing acceptanceFiled (NDA/BLA)Versamune HPV · FDA clearance decision on amended IND for VERSATILE-003 Phase 3 trialSEC 8-K
- October 2, 2024conferencedata presentationsecondaryPhase 2Versamune HPV · Updated data from the IMMUNOCERV Phase 2 trial presented at ASTRO Annual Meeting 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-15HC Wainwright & Co.Buy
- 2025-11-25B. Riley SecuritiesBuy
- 2025-11-13HC Wainwright & Co.Buy
- 2025-07-01HC Wainwright & Co.Buy
- 2025-06-11HC Wainwright & Co.Buy
- 2025-03-27HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-10PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal - Stock Titan
- 2026-07-06PDS Biotechnology Q1 2026 Earnings: Narrower-than-expected loss highlights clinical focus - Earnings Per Share - dars.gov.et
- 2026-07-05PDSB Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Advances - Pre-Earnings Drift - dars.gov.et
- 2026-06-27Enterprise value to revenue forward of PDS Biotechnology Corporation – NASDAQ:PDSB - TradingView
- 2026-06-26PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
- 2026-06-25PDSB Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-15PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program - Stock Titan
- 2026-06-15PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.